The enhanced clinical benefits of alpha-1 antitrypsin (AAT) therapy in severe AAT deficiency (AATD) were identified in a new study published in the American Journal of Respiratory Critical Care Medicine.
While AAT therapy reduces protease-mediated lung tissue destruction and retards emphysema progression, there is also growing evidence regarding the anti-inflammatory and immunomodulatory properties of AAT.
A pilot study conducted on patients with AATD demonstrated the effects of double-dose AAT therapy in normalizing AAT levels. This study further explored this aspect of AAT therapy by using several databases and classification systems which helped the researchers identify various protein-protein interaction modules, providing evidence for a strong interaction between the group of cytokines, chemokines, and growth factors significantly downregulated by double-dose AAT therapy.
The study also provided evidence for strong interactions between AAT and other biological markers like macrophage colony-stimulating factor and tumor necrosis factor-alpha.
Read more about AATD therapies
The results of this research highlight the anti-inflammatory and immunomodulatory effects of AAT therapy. The study team encourages further investigation to identify the potential benefits of AAT therapy for a wider range of inflammatory disorders.
Campos MA, Geraghty P. Cytokine regulation by alpha-1 antitrypsin therapy: a pathway analysis of a pilot clinical trial. Am J Respir Cell Mol Biol. 2022;66(6):697-700. doi:10.1165/rcmb.2021-0503LE